Hearing function in soft tissue sarcoma patients after treatment with carboplatin: A report from the Late Effects Surveillance System

W. Stöhr; T. Langer; A. Kremers; I. Brecht; J. Treuner; A. Dinnesen; J. D. Beck

doi:10.3892/or.12.4.767

Hearing function in soft tissue sarcoma patients after treatment with carboplatin: A report from the Late Effects Surveillance System

W. Stöhr, T. Langer, A. Kremers, I. Brecht, J. Treuner, A. Dinnesen, J. D. Beck^*

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Kinder- und Jugendmedizin

12 Zitate (Scopus)

Abstract

The aim of this study was to analyse carboplatin-induced ototoxicity in a recent study trial. Twenty patients who had received carboplatin for the treatment of soft tissue sarcoma were investigated prospectively for ototoxicity in a multi-centre trial. Hearing function was tested by audiometry. All patients but one were treated with a cumulative dose of 1500 mg/m², the remaining with 500 mg/m². We evaluated the incidence and dependencies of hearing loss, and compared hearing thresholds to those of an untreated control group (n=60). Hearing thresholds in the carboplatin treated group were only marginally poorer compared with those of the control group. After carboplatin therapy no patient (0%; 95%-KI: 0-17%) had a hearing loss >20 dB. Hearing thresholds were not dependent on age, sex or cranial irradiation. We conclude that ototoxicity after carboplatin was low in our group of patients.

Originalsprache	Englisch
Zeitschrift	Oncology Reports
Jahrgang	12
Ausgabenummer	4
Seiten (von - bis)	767-771
Seitenumfang	5
ISSN	1021-335X
DOIs	https://doi.org/10.3892/or.12.4.767
Publikationsstatus	Veröffentlicht - 10.2004

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Dokumente

10.3892/or.12.4.767

Weitere Links

Link to publication in Scopus

Zitieren

@article{e1a7fea385f546aeab59ffbeb6604df2,

title = "Hearing function in soft tissue sarcoma patients after treatment with carboplatin: A report from the Late Effects Surveillance System",

abstract = "The aim of this study was to analyse carboplatin-induced ototoxicity in a recent study trial. Twenty patients who had received carboplatin for the treatment of soft tissue sarcoma were investigated prospectively for ototoxicity in a multi-centre trial. Hearing function was tested by audiometry. All patients but one were treated with a cumulative dose of 1500 mg/m2, the remaining with 500 mg/m2. We evaluated the incidence and dependencies of hearing loss, and compared hearing thresholds to those of an untreated control group (n=60). Hearing thresholds in the carboplatin treated group were only marginally poorer compared with those of the control group. After carboplatin therapy no patient (0%; 95%-KI: 0-17%) had a hearing loss >20 dB. Hearing thresholds were not dependent on age, sex or cranial irradiation. We conclude that ototoxicity after carboplatin was low in our group of patients.",

author = "W. St{\"o}hr and T. Langer and A. Kremers and I. Brecht and J. Treuner and A. Dinnesen and Beck, {J. D.}",

year = "2004",

month = oct,

doi = "10.3892/or.12.4.767",

language = "English",

volume = "12",

pages = "767--771",

journal = "Oncology Reports",

issn = "1021-335X",

number = "4",

}

TY - JOUR

T1 - Hearing function in soft tissue sarcoma patients after treatment with carboplatin: A report from the Late Effects Surveillance System

AU - Stöhr, W.

AU - Langer, T.

AU - Kremers, A.

AU - Brecht, I.

AU - Treuner, J.

AU - Dinnesen, A.

AU - Beck, J. D.

PY - 2004/10

Y1 - 2004/10

N2 - The aim of this study was to analyse carboplatin-induced ototoxicity in a recent study trial. Twenty patients who had received carboplatin for the treatment of soft tissue sarcoma were investigated prospectively for ototoxicity in a multi-centre trial. Hearing function was tested by audiometry. All patients but one were treated with a cumulative dose of 1500 mg/m2, the remaining with 500 mg/m2. We evaluated the incidence and dependencies of hearing loss, and compared hearing thresholds to those of an untreated control group (n=60). Hearing thresholds in the carboplatin treated group were only marginally poorer compared with those of the control group. After carboplatin therapy no patient (0%; 95%-KI: 0-17%) had a hearing loss >20 dB. Hearing thresholds were not dependent on age, sex or cranial irradiation. We conclude that ototoxicity after carboplatin was low in our group of patients.

AB - The aim of this study was to analyse carboplatin-induced ototoxicity in a recent study trial. Twenty patients who had received carboplatin for the treatment of soft tissue sarcoma were investigated prospectively for ototoxicity in a multi-centre trial. Hearing function was tested by audiometry. All patients but one were treated with a cumulative dose of 1500 mg/m2, the remaining with 500 mg/m2. We evaluated the incidence and dependencies of hearing loss, and compared hearing thresholds to those of an untreated control group (n=60). Hearing thresholds in the carboplatin treated group were only marginally poorer compared with those of the control group. After carboplatin therapy no patient (0%; 95%-KI: 0-17%) had a hearing loss >20 dB. Hearing thresholds were not dependent on age, sex or cranial irradiation. We conclude that ototoxicity after carboplatin was low in our group of patients.

UR - http://www.scopus.com/inward/record.url?scp=16644377519&partnerID=8YFLogxK

U2 - 10.3892/or.12.4.767

DO - 10.3892/or.12.4.767

M3 - Journal articles

C2 - 15375498

AN - SCOPUS:16644377519

SN - 1021-335X

VL - 12

SP - 767

EP - 771

JO - Oncology Reports

JF - Oncology Reports

IS - 4

ER -

Hearing function in soft tissue sarcoma patients after treatment with carboplatin: A report from the Late Effects Surveillance System

Abstract

Strategische Forschungsbereiche und Zentren

UN SDGs

Dokumente

Weitere Links

Fingerprint

Zitieren